Skip to main content
Log in

Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors

  • Clinical Studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Sixteen patients with recurrent childhood brain tumors were treated with intravenous cisplatin, cytosine arabinoside and etoposide (PAE), daily for three days every three to four weeks. Objective responses were observed in 6 of 15 evaluable patients and an additional six patients had stable disease for > 6 months. The tumor-specific response rate for astrocytoma/glioma was 3 of 7 and for medulloblastoma was 2 of 4. The mean progression-free interval was 11.0 months and the hazard rate for progression was 0.085 per patient-month of observation. The most common toxicities were neutropenia and thrombocytopenia. Clinically significant ototoxicity wasidentified in 7 patients. The activity of PAE chemotherapy for recurrent childhood brain tumors warrants further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Khan AB, D'Souza BJ, Wharam MD, et al.: Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep 66: 2013–2020, 1982

    Google Scholar 

  2. Sexauer CL, Khan A, Burger PC, et al.: Cisplatin in recurrent pediatric brain tumors. A POG phase II study. A Pediatric Oncology Group study. Cancer 56: 1497–1501, 1985

    Google Scholar 

  3. Walker RW, Allen JC: Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol 6: 62–66, 1988

    Google Scholar 

  4. Bertolone SJ, Baum ES, Krivit W, Hammond GD: A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Study Group. J Neuro-Oncol 7: 5–11, 1989

    Google Scholar 

  5. Tirelli V, D'Incalci M, Canetta R, et al.: Etoposide (VP-16213) in malignant brain tumors: a phase II study. J Clin Oncol 2: 432–437, 1984

    Google Scholar 

  6. Durand RE, Goldie JH: Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 71: 673–679, 1987

    Google Scholar 

  7. Crist WM, Raney RB, Rageb A, et al.: Intensive chemotherapy including cisplatin with or without etoposide for children with soft-tissue sarcomas. Med Pediatr Oncol 15: 51–57, 1987

    Google Scholar 

  8. Kovner EH, Kellie SJ, Horowitz ME, et al.: Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: A phase II study. J Clin Oncol 8: 330–336, 1990

    Google Scholar 

  9. Bergerat JP, Drewinko B, Corry P, et al.: Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-β-D-arabi-nofuranosyl cytosine. Cancer Res 41: 25–30, 1981

    Google Scholar 

  10. Stewart DJ, Richard MT, Benoit B, et al.: Cisplatin plus cytosine arabinoside in adults with malignant gliomas. J Neuro-Oncol 2: 29–34, 1984

    Google Scholar 

  11. Strauss LC, Killmond T, Maria BL, Carson B, Wharam M: Primary chemotherapy with cisplatin and VP-16 in children under 36 months old with brain tumors. Proc Am Soc Clin Oncol 5: 84, 1984 (abstr)

    Google Scholar 

  12. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. JASA 53: 457–481, 1958

    Google Scholar 

  13. Edwards MS, Levin VA, Wilson CB: Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 64: 1179–1205, 1980

    Google Scholar 

  14. Friedman HS, Colvin OM, Skapek SX, et al.: Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48: 4189–4195, 1988

    Google Scholar 

  15. Diez B, Monges J, Muriel FS: Evaluation of cisplatin in children. Cancer Treat. Rep. 69: 911–913, 1985

    Google Scholar 

  16. Granowetter L, Rosenstock JG, Packer RJ: Enhanced cisplatinum neurotoxicity in pediatric patients with brain tumors. J Neuro-Oncol 1: 293–297, 1983

    Google Scholar 

  17. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34: 934–938, 1984

    Google Scholar 

  18. Powell BL, Capizzi RL, Lyerly ES, Cooper MR: Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin and asparaginase consolidation for acute non-lymphocytic leukemia. J Clin Oncol 4: 95–97, 1986

    Google Scholar 

  19. Russel JA, Powdes RL: Neuropathy due to cytosine arabinoside. Br Med J 4: 652–653, 1974

    Google Scholar 

  20. Falkson G, van Dyk JJ, van Eden EB, et al.: A clinical trial of the oral form of 4′-dimethyl-epipodophyllotoxin-β-D-ethylidene glucoside (NSC-141540) (VP-16–213). Cancer 35: 1141–1144, 1975

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corden, B.J., Strauss, L.C., Killmond, T. et al. Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors. J Neuro-Oncol 11, 57–63 (1991). https://doi.org/10.1007/BF00166998

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00166998

Key words

Navigation